Optimi Health Corp. announced that it has entered into a CAD 1.2 million definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through pre-clinical research and clinical trials. Under Canada's Controlled Drugs and Substances regulations, Optimi functions as an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine ("MD"), natural GMP-grade psilocybin, and high-quality functional mushrooms. To fulfill its obligations, Optimi is cultivating dried GMP psilocybin-containing biomass and extract into a refined substance, which will be distributed to the Client's international research sites.

This announcement affirms Optimi's commitment to GMP production capabilities and its ability to supply large scale research and development programs. This latest agreement helps to fulfill the goal of Optimi's founders in making the Company a true multinational participant in the research and development of psychedelic medicines.